Introduction
Peritoneal implants are detected in approximately 10% of the patients at time of primary colorectal cancer resection. 1, 2 Furthermore, the peritoneal cavity is the only site of metastatic disease in 25% of patients with colorectal cancer recurrence. [2] [3] [4] The two proposed mechanisms for the intraperitoneal (i.p.) spread of intraabdominal tumors 5 are natural tumor progression and surgical manipulation. During tumor progression, i.p. spread may occur as a result of full-thickness invasion of the bowel wall. Peritoneal seeding may also occur as a result of tumor rupture or organ rupture, such as with mucus-producing cystadenocarcinoma of the appendix.
Iatrogenic i.p. spread may occur during surgery from tumor cells spilled from dissected lymph vessels or from transected viscera. Tumor cells can also theoretically reach the peritoneal cavity through hemorrhage into the surgical field. Peritoneal colorectal carcinomatosis is associated with high morbidity and mortality. Regional delivery of therapeutic agents (for example, i.p. administration) remains an active area of clinical investigation. 6, 7 hrR3 is a herpes simplex virus 1 (HSV-1) mutant defective in viral ribonucleotide reductase. 8 In earlier work, we demonstrated that hrR3 replicates preferentially in liver metastases rather than in the normal liver. 9, 10 A single intravascular administration of hrR3 significantly reduces tumor burden and enhances survival in mice bearing diffuse colorectal liver metastases. 11 Pre-existing immunity to HSV-1 does not reduce antitumor efficacy. 12 , 13 Here we investigate in a murine model of syngeneic peritoneal colon carcinoma metastases any differences in the biodistribution and efficacy of hrR3 as a function of route of administration. We demonstrate that the i.p. administration of hrR3 leads to a more restricted systemic biodistribution of virus than the intravenous (i.v.) treatment. The more restricted biodistribution observed following i.p. delivery compared with i.v. delivery was also associated with a higher LD 50 . Furthermore, overall survival of animals is significantly prolonged in i.p. treated mice as compared with i.v. treated animals.
Materials and methods

Cell lines and viruses
The human colon carcinoma cell lines HT29 and SW480, as well as the African Green Monkey kidney cell line Vero, were obtained from the American Type Culture Collection (Rockville, MD). The MC26 mouse colon carcinoma cell line was obtained from the National Cancer Institute Tumor Repository (Frederick, MD). All cell lines were maintained in Dulbecco's modified Eagle's medium, 10% fetal bovine serum, 100 U ml À1 penicillin and 100 g ml À1 streptomycin. The HSV-1 vector, hrR3 8 (kindly provided by Sandra Weller, University of Connecticut, New Haven, CT), is comprised of an insertion of the lacZ gene into the UL39 locus of the parent virus, KOS. F strain herpes simplex virus was obtained from Antonia Chiocca (Ohio State University, Columbus, OH). The viruses were propagated and titered on Vero cells.
Viral cytotoxicity assays
Viral cytotoxicity assays were performed as described earlier. 10 Briefly, cells were plated onto 96-well plates at 5000 cells per well for 36 h. Virus was added at multiplicity of infection (MOI) values ranging from 0.001 to 10 and incubated for 6 days. The number of surviving cells was quantitated using a colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Experiments were performed in triplicate. MC26 cells in 500 ml phosphate-buffered saline (n ¼ 5 per group). Beginning on day 4, mice were treated i.p. or i.v. with 1 Â 10 8 plaque-forming units (PFU) hrR3 every other day for a total of three doses. Mice were killed 48 h after the last dose, and the presence of virus was assessed by PCR amplification of HSV-1-specific sequences from tissue samples including tumor and normal bowel, liver, spleen, kidney, lung, heart and brain.
Animal studies
LD 50 was assessed by a single inoculation of a variety of doses of F strain into A/J mice. The mice (n ¼ 5 per group) were followed 10 days for signs of morbidity or mortality. Mice were randomized to either i.v. or i.p. administration. As per the institutionally approved protocol, doses above LD 50 were not tested.
To assess macroscopic differences in tumor progression, peritoneal metastases were induced by i.p. injection of a single-cell suspension consisting of 1 Â 10 5 MC26 cells in 500 ml phosphate-buffered saline (n ¼ 3 per group). Beginning on day 4, mice were treated with three doses of 1 Â 10 8 PFU hrR3 either i.p. or i.v. every other day. Control animals received mock-infected media. Twenty days after tumor induction, all mice were killed and their tumor burden was examined. All abdominal organs (the liver, stomach, small and large bowel, mesentery, kidneys, spleen, omentum and all associated tumors) were removed en bloc. Abdominal organ specimens from mice naive to virus and tumor were removed en bloc in a similar fashion and a baseline weight was established. Tumor weight was determined by subtracting the average naive animals' (baseline) abdominal organ weight from the weights of abdominal organ specimens.
To examine the effect of route of administration on survival of mice bearing peritoneal colorectal metastases, mice were randomized to receive hrR3 by either i.p. or i.v. administration. Control animals received i.p. mockinfected media. On day 0, Balb/c mice were injected i.p. with a single-cell suspension consisting of 1 Â 10 5 MC26 cells in 500 ml phosphate-buffered saline. On days 4, 6 and 8, i.p. or i.v. treatment of 1 Â 10 8 PFU hrR3 (in a volume of 500 ml for i.p. injections and 100 ml for i.v. injections) was performed (n ¼ 10 per group). Survival times were monitored and distribution was displayed by the method of Kaplan and Meier. Experiments were repeated once to ensure reproducibility.
PCR assay PCR amplification of HSV-1-specific sequences to investigate the biodistribution of HSV-1 in mice was performed as described. 13 Forward oligonucleotide primer 5 0 -GGAGGCGCCCAAGCGTCCGGCCG-3 0 and reverse oligonucleotide primer 5 0 -TGGGGTACAGGCT GGCAAAGT-3 0 were used to amplify a 229-bp fragment of HSV-1 DNA polymerase gene. DNA was extracted from BALB/c mouse tissues using the MasterPure Purification kit (Epicentre, Madison, WI) following the manufacturer's instructions. PCR amplifications were performed on 100 ng of DNA in a volume of 25 11, [14] [15] [16] Mice were randomized to treatment with 1 Â 10 8 PFU hrR3 by i.v. or i.p. delivery every other day for a total of three doses. Forty-eight hours after the last dose, biodistribution was assessed by PCR amplification of HSV-1-specific sequences from tissue samples including tumor and normal gut, liver, spleen, kidney, lung, heart and brain (Figure 1 ). The frequency of detection by PCR of hrR3 in tumors was essentially similar in i.p. and i.v. treated mice, although the 'effective' MOI was higher in the i.p. group relative to the i.v. group. The location of lacZ staining detected histochemically in the tumor nodules did not differ between i.v. and i.p. administration mice. Importantly, i.p. administration resulted in a reduced frequency of hrR3 detection in normal tissues such as kidney, lung, heart and brain (Table 1) .
To determine if a reduced toxicity is also observed with this more restricted biodistribution, LD 50 was assessed following i.p. or i.v. administration of F strain in mice. Initial experiments revealed no balb/c mouse mortality following administration of even the highest achievable titers of hrR3, KOS and F strains, and we therefore instead tested AJ mice, which are more sensitive to HSV-1 mortality. Although the LD 50 of i.v. administration of F strain was determined to be approximately 1 Â 10 7 PFU, the LD 50 of i.p. administration could not be reached because of stock viral titer limitations, but it is demonstrated to be higher than 1 Â 10 8 PFU (Table 2) . Thus, the more restricted biodistribution observed following i.p. delivery compared with i.v. delivery was also associated with reduced toxicity and a higher LD 50 .
In mice bearing peritoneal colorectal metastases, i.p. administration of hrR3 reduces tumor burden and enhances survival hrR3 is cytotoxic to MC26 murine colon carcinoma cells and the human colon carcinoma cell lines HT29 and SW480 at low MOIs (Figure 2 ). Because herpes viruses have a greater tropism for human cell lines, it is not surprising that the murine MC26 cell line was less susceptible to lytic oncolysis than the human colon cancer cell lines. We measured in vivo antineoplastic efficacy against MC26 peritoneal metastases following either i.p. or i.v. administration. Mice bearing MC26 colon carcinoma peritoneal metastases were established as above and randomized to receive i.p. or i.v. injections of 1 Â 10 8 PFU hrR3 (n ¼ 4 for each group) on days 4, 6 and 8. Control animals received mock-infected media i.p. Twenty days after tumor induction, all mice were killed and their tumor burden was examined (Figure 3a) . I.p. administered hrR3 reduced tumor burden from 280 ± 98 mg in controls to 72±48 mg (Po0.01). Systemic administration of hrR3 had no effect on tumor burden. These animals had comparable tumor burden (290 ± 141 mg) as the control animals (Figure 3b) .
To examine the effect of route of administration on survival of mice bearing peritoneal colorectal metastases, mice were randomized to receive hrR3 by either i.p. or i.v. administration. Control animals received mock-infected media i.p. On day 0, Balb/C mice were injected i.p. with a single-cell suspension consisting of 1 Â 10 5 MC26 cells in 500 ml phosphate-buffered saline, followed by i.p. or i.v. Table 1 . GAPDH, glyceraldehyde 3-phosphate dehydrogenase ; HSV-1, herpes simplex virus 1; i.p., intraperitoneal; i.v., intravenous. (Figure 4) . The i.p. group had two long-term survivors, which were killed on day 78. Necropsy revealed minimal tumor burden in these animals, and necropsy of other mice demonstrated that they died of overwhelming tumor burden. Median survival of animals in the control, i.v. and i.p. groups were 22, 24 and 37 days, respectively. The difference in survival between the i.p. group and the i.v. group was statistically significant (Po0.01). There was no significant difference between i.v. treated and control groups. These results indicate that in mice bearing peritoneal metastases, regional delivery of the hrR3 oncolytic virus has antineoplastic effects, whereas systemic delivery does not have.
Discussion
Viral oncolysis represents a therapeutic approach that exploits the natural process of lytic viral replication as a means to destroy tumors. 17 As hrR3 is deficient in the large subunit of ribonucleotide reductase, it replicates preferentially in cells with high intracellular nucleotide pools. 18 For example, hrR3 preferentially replicates in colon carcinoma rather than in normal hepatocytes, 9, 10 and a single intravascular (intrasplenic) injection of hrR3 significantly reduces liver tumor burden. 11 Several strategies have been investigated to restrict viral replication to tumor cells (rather than normal cells) including modulation of surface receptors, 19 deletion of critical viral genes that are complemented preferentially by tumor cells, 9 use of promoters for tumor-associated antigen to drive critical genes critical to viral replication 20 and regional virus administration. 21 Hepatic arterial administration has been favored as a delivery route to achieve preferential distribution to liver tumors rather than to the normal liver. 22 Similarly, i.p. administration has been examined as a delivery route to achieve preferential distribution to small peritoneal nodules. 6, 7 Earlier preclinical studies have evaluated the therapeutic efficacy of i.p. injected HSV-1 mutants against peritoneal implants, but all these studies were conducted in nude mice bearing human peritoneal cancer xenografts. For example, in a peritoneal disseminated pancreatic cancer xenograft, i.p. hrR3 was shown to be effective. 23 Coukos et al. 24 investigated the effect of another HSV-1 mutant (G207) in a human epithelial ovarian cancer mouse xenograft model. Bennett et al. 25 treated peritoneally disseminated gastric cancer cells in a mouse xenograft model using two different HSV-1 mutants, and demonstrated a significant reduction in tumor burden and prolongation of survival. But as noted above, all of these studies were conducted in immunodeficient mice bearing human tumors, which precludes a reliable and accurate comparison of biodistribution to tumor versus normal tissues, as human cells are much more susceptible to herpes infection than murine cells.
Here we compared the impact of route of administration (i.p. versus i.v.) on therapeutic efficacy and biodistribution in immunocompetent mice with syngeneic murine colon carcinoma peritoneal metastases. Inoculation of hrR3 through the i.p. route of administration leads to a more restricted biodistribution and reduced toxicity (higher LD 50 ). The i.p. route was also more efficacious in reducing tumor burden and prolonging survival relative to the i.v. route. Additional theoretical advantages of i.p. The dose that was selected for comparing the two routes of delivery proved to be ineffective against the peritoneal metastases following i.v. administration. However, hrR3 was detected in peritoneal tumor samples. The lack of antineoplastic efficacy despite the presence of hrR3 in peritoneal tumors after i.v. treatment was most likely secondary to an 'effective MOI' that was too low. I.p. administration increases direct contact between tumor cells and viral particles. We and others have shown that the induction of immunity against HSV-1 before HSV-1 administration does not reduce oncolytic efficacy; 12, 13 however, natural immunity and other defenses in the vascular compartment may reduce the effective MOI. 26 The innate immune system has been demonstrated to sequester infected cells as well as free viral particles, thereby reducing oncolytic efficacy. 27 Virus delivered i.v. is more susceptible to the neutralizing effects of innate immunity than virus administered i.p. or directly into a tumor. In addition, the blood supply to peritoneal metastases has been shown to be quite limited, leading to a reduced bioavailability of systemically administered virus. 28 Our results provide support to i.p. administration of oncolytic agents as a means to both increase efficacy against peritoneal metastases and limit toxicity.
Intraperitoneal HSV-1 oncolysis could theoretically be combined with other i.p. therapies. For example, an improved survival in patients with peritoneal dissemination of colorectal cancer after treatment with surgical cytoreduction followed by hyperthermic i.p. chemotherapy has been reported. 29 In addition, in selected gastric cancer patients, i.p. chemotherapy compared with surgery, 30 or hyperthermic i.p. chemotherapy compared with either surgery alone or normothermic i.p. chemotherapy, resulted in higher survival rates. 31 Hyperthermia has been shown to improve drug potency as well as tissue penetration. 32 Unfortunately, hyperthermia is inhibitory to lytic HSV-1 replication, 33, 34 including replication of infected cell protein 6 (ICP6)-defective HSV-1 mutants such as hrR3. 35 Cytotoxic chemotherapy also appears to Thus, additional studies examining chemotherapy-and hyperthermia-induced modulation of cellular pathways that are intimately linked to viral replication are required to gain a better understanding of how to involve oncolytic HSV-1 as a part of multimodality approach to treatment.
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